Preliminary Results in Unresectable XXXX Treated by Radiofrequency and Microwave Ablation: Feasibility, Efficacy, and Safety.

@entity5 @entity135 @entity1 @entity75
PURPOSE: To retrospectively determine whether the application of thermal ablation to recurrent and advanced @entity135 ( @entity135 ) could allow for @entity5 control. MATERIALS AND METHODS: From 2002 to 2014, 22 @entity1 (17 @entity1 and 5 @entity1 ; mean age, 64 y; age range, 42-88 y) with unresectable @entity135 lesions treated with thermal ablation were evaluated. @entity1 were followed at 3 and 6 months after treatment, every 6 months for 5 years, and yearly thereafter with computed tomography and/or magnetic resonance imaging. The mean follow-up period was 32.2 months (range, 3-51 mo). RESULTS: Three of 22 @entity1 with @entity75 are still alive; two of these @entity1 were treated with radiofrequency (RF) ablation and one was treated with microwave (MW) ablation. Of the 19 remaining @entity1 , four were treated with MW ablation and 15 were treated with RF ablation. Imaging revealed partial response in eight @entity1 , and complete response was observed in the remaining 14. There were two major complications after ablation treatment. The mean survival time was 32.9 months    3.205 (standard error; 95% confidence interval [CI], 26.6-39.2 mo). The survival time for MW ablation cases (36 mo    5.185; 95% CI, 25.8-46.16 mo) was longer than for RF ablation (32.2 mo    3.911; 95% CI, 24.5-39.8 mo), although the CI overlap between the groups is large. CONCLUSIONS: Percutaneous thermal ablation is a promising alternative treatment for local control of incurable @entity135 .
